463
Participants
Start Date
March 16, 2021
Primary Completion Date
May 11, 2022
Study Completion Date
May 11, 2022
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)
Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
Meningococcal group A, C, W-135, and Y conjugate vaccine
Pharmaceutical form: Powder and solvent for solution for injection Route of administration: Intramuscular
Human Papillomavirus 9-valent Vaccine (9vHPV)
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Investigational Site Number :3480003, Budapest
Investigational Site Number :3480002, Miskolc
Investigational Site Number :3480004, Szigetvár
Investigational Site Number :3480006, Szombathely
Investigational Site Number :3480001, Győr
Investigational Site Number :7240011, Burriana
Investigational Site Number :7240006, Santiago de Compostela
Investigational Site Number :3800002, Milan
Investigational Site Number :7240003, Madrid
Investigational Site Number :7240001, Seville
Investigational Site Number :7240008, Valencia
Investigational Site Number :7240004, Valencia
Investigational Site Number :7240009, Valencia
Investigational Site Number :7240010, Valencia
Investigational Site Number :7240012, Valencia
Investigational Site Number :7240007, Puçol
Investigational Site Number :3800005, Foggia
Investigational Site Number :3800006, Catanzaro
Investigational Site Number :3800004, Palermo
Investigational Site Number :7020002, Singapore
Investigational Site Number :3800001, Genova
Investigational Site Number :7240002, Barcelona
Investigational Site Number :7240005, Esplugues de Llobregat
Sanofi Pasteur, a Sanofi Company
INDUSTRY